Preclinical pharmacology and safety of a novel avidin derivative for tissue-targeted delivery of radiolabelled biotin

Basic and Clinical Pharmacology and Toxicology

Volumn 109, Issue 3, 2011, Pages 145-155

  Petronzelli, Fiorella ^a   Anastasi, Anna M ^a   Pelliccia, Angela ^a   Santapaola, Daniela ^a   Albertoni, Claudio ^a   Rosi, Antonio ^a   Leoni, Barbara ^a   Ferrari, Liliana E ^a   Paganelli, Giovanni ^b   Gramiccioli, Giancarlo ^a   Pesce, Daniela ^a   Alfano, Anna M ^a   Stasi, Maria A ^a   De Santis, Rita ^a  

^a Sigma Tau SpA   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AVIDIN; AVIDINOX; BIOTIN; OXIDIZED AVIDIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN 3T3; CELL VIABILITY; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; HAPLORHINI; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; ISOTOPE LABELING; MALE; MOUSE; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN CELL;

3T3 CELLS; ANIMALS; APOPTOSIS; AVIDIN; BIOTIN; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; INDIUM RADIOISOTOPES; KIDNEY; LIVER; MACACA FASCICULARIS; MALE; MICE; MUSCLE, SKELETAL; MUTAGENICITY TESTS; RADIOPHARMACEUTICALS; RATS; SALMONELLA TYPHIMURIUM; TOXICITY TESTS;

EUKARYOTA; PRIMATES; PROKARYOTA; RATTUS; RODENTIA;

EID: 79959301042     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00701.x     Document Type: Article

References (30)

1. Paganelli G, De Cicco C, Ferrari ME, Carbone G, Pagani G, Leonardi MC et al. Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: results of a phase II study with (90)Y-labeled biotin. Eur J Nucl Med Mol Imaging 2010;37:203-11.
2. Paganelli G, Ferrari M, Ravasi L, Cremonesi M, De Cicco C, Galimberti V et al. Intraoperative avidination for radionuclide therapy: a prospective new development to accelerate radiotherapy in breast cancer. Clin Cancer Res 2007;13(18 Pt 2):5646s-51s.
3. Paganelli G, Ferrari M, Cremonesi M, De Cicco C, Galimberti V, Luini A et al. IART: intraoperative avidination for radionuclide treatment. A new way of partial breast irradiation. Breast 2007;16:17-26.
4. Urbano N, Papi S, Ginanneschi M, De Santis R, Pace S, Lindstedt R et al. Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT). Eur J Nucl Med Mol Imaging 2007;34:68-77.
5. Melamed MD, Green NM. Avidin. 2. Purification and composition. Biochem J 1963;89:591-9.
6. Yao Z, Zhang M, Sakahara H, Nakamoto Y, Higashi T, Zhao S et al. The relationship of glycosylation and isoelectric point with tumor accumulation of avidin. J Nucl Med 1999;40:479-83.
7. Wiig H, Gyenge CC, Tenstad O. The interstitial distribution of macromolecules in rat tumours is influenced by the negatively charged matrix components. J Physiol 2005;567(Pt 2):557-67.
8. Verdoliva A, Bellofiore P, Rivieccio V, Catello S, Colombo M, Albertoni C et al. Biochemical and biological characterization of a new oxidized avidin with enhanced tissue binding properties. J Biol Chem 2010;285:9090-9.
9. De Santis R, Albertoni C, Rosi A, Leoni B, Petronzelli F, D'Alessio V et al. OXavidin for tissue targeting biotinylated therapeutics. J Biomed Biotechnol 2009;2009:921434.
10. De Santis R, Leoni B, Rosi A, Albertoni C, Forni G, Cojoca R et al. AvidinOX for highly efficient tissue-pretargeted radionuclide therapy. Cancer Biother Radiopharm 2010;25:143-8.
11. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999;344(Pt 1):109-16.
12. Thornalley PJ. Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems - role in ageing and disease. Drug Metabol Drug Interact 2008;23:125-50.
13. Avigad G. A simple spectrophotometric determination of formaldehyde and other aldehydes: application to periodate-oxidized glycol systems. Anal Biochem 1983;134:499-504.
14. Chaiet L, Wolf FJ. The properties of streptavidin, a biotin-binding protein produced by Streptomycetes. Arch Biochem Biophys 1964;106:1-5.
15. Clive D, Johnson KO, Spector JF, Batson AG, Brown MM. Validation and characterization of the L5178Y/TK+/- mouse lymphoma mutagen assay system. Mutat Res 1979;59:61-108.
16. Robinson WD, Green M, Cole J, Healy MJR, Garner RC, Gatehouse D. Statistical evaluation of bacterial/mammalian fluctuation tests. In: Kirkland DJ (ed.). Statistical Evaluation of Mutagenicity Test Data. Cambridge University Press, 1989;102-40.
17. Maron DM, Ames BN. Revised methods for the Salmonella mutagenicity test. Mutat Res 1983;113:173-215.
18. Petronzelli F, Pelliccia A, Anastasi AM, Lindstedt R, Manganello S, Ferrari LE et al. Therapeutic use of avidin is not hampered by antiavidin antibodies in humans. Cancer Biother Radiopharm 2010;25:563-70.
19. Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer 2002;86:207-12.
20. Paganelli G, Chinol M, Maggiolo M, Sidoli A, Corti A, Baroni S et al. The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy. Eur J Nucl Med 1997;24:350-1.
21. Paganelli G, Grana C, Chinol M, Cremonesi M, De Cicco C, De BF et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 1999;26:348-57.
22. Cianfriglia M, Armellini D, Massone A, Mariani M. Simple immunization protocol for high frequency production of soluble antigen-specific hybridomas. Hybridoma 1983;2:451-7.
23. Marshall DT. Options and recent advances in permanent brachytherapy for prostate cancer. Can J Urol 2007;14(Suppl. 1):28-31.
24. Dale GL, Gaddy P, Pikul FJ. Antibodies against biotinylated proteins are present in normal human serum. J Lab Clin Med 1994;123:365-71.
25. Bubb MO, Green F, Conradie JD, Tchernyshev B, Bayer EA, Wilchek M. Natural antibodies to avidin in human serum. Immunol Lett 1993;35:277-80.
26. Cox JE. Egg-based vaccines. Pediatr Rev 2006;27:118-9.
27. Paganelli G, Magnani P, Fazio F. Pretargeting of carcinomas with the avidin-biotin system. Int J Biol Markers 1993;8:155-9.
28. Withers HR. Cell cycle redistribution as a factor in multifraction irradiation. Radiology 1975;114:199-202.
29. Dolinsky C, Glatstein E. Some cases of severe normal tissue toxicity can be anticipated with ablated fractionated radiation with appropriate long-term follow-up. Semin Radiat Oncol 2008;18:229-33.
30. Dalakas MC. Toxic and drug-induced myopathies. J Neurol Neurosurg Psychiatry 2009;80:832-8.